Palisade Bio, Inc. (PALI) vs Cartesian Therapeutics, Inc. (RNAC)

Palisade Bio, Inc. and Cartesian Therapeutics, Inc. are both Biotechnology companies. Palisade Bio, Inc. and Cartesian Therapeutics, Inc. are of similar size ($205.1M and $202.2M). Cartesian Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Palisade Bio, Inc. trades at 1.8×. Palisade Bio, Inc. grew revenue faster over the last twelve months: 5,492.6% against −94.8%. Cartesian Therapeutics, Inc. has the higher net margin (0.00% vs −4,230.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Cartesian Therapeutics, Inc. leads on 10 and Palisade Bio, Inc. on 6.

Valuation

Metric PALI RNAC Biotechnology median
P/E 1.76 n/m 10.60
P/S 319.17 125.84 9.40
P/B 1.98 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 154.02 78.22 9.02
Earnings yield 56.81% (78.23%) (32.88%)
Free cash flow yield (7.55%) (35.20%) (23.13%)

Profitability

Metric PALI RNAC Biotechnology median
Gross margin 95.63% 100.00% 68.51%
Operating margin (4,681.99%) 0.00% 0.00%
Net margin (4,230.60%) 0.00% 0.00%
Free cash flow margin (2,409.27%) 0.00% 0.00%
Return on equity (51.37%) 236.88% (51.96%)
Return on assets (47.68%) (42.77%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PALI RNAC Biotechnology median
Revenue growth (TTM) 5,492.59% (94.81%) 6.76%
EPS growth (last fiscal year) 97.06% (11.80%) 29.88%
Revenue growth, 5-year CAGR 72.86% (29.96%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PALI RNAC Biotechnology median
Debt to equity 0.00 (0.42) 0.00
Current ratio 24.26 7.48 4.97
Net debt to EBITDA 7.37 0.89 1.01

Dividend

Metric PALI RNAC Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PALI RNAC Biotechnology median
Market cap 202.16m 205.13m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack